Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Literature DB >> 20551894

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Shi-Ming Tu¹, Sue-Hwa Lin, Donald A Podoloff, Christopher J Logothetis.

Abstract

Accumulating data suggest that bone-seeking radiopharmaceuticals can be used to treat prostate cancer bone metastasis and improve the clinical outcome of patients with advanced prostate cancer. It remains to be elucidated whether radiopharmaceuticals enhance the disruption of the onco-niche or the eradication of micrometastatic cells in the bone marrow. The purpose of this review is to investigate the role of bone-targeted radioisotope therapy in the setting of multimodality therapy for advanced prostate cancer. We examine available data and evaluate whether dose escalation, newer generations, or repeated dosing of radiopharmaceuticals enhance their antitumor effects and whether their combination with hormone ablative therapy, chemotherapy, or novel targeted therapy can improve clinical efficacy.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20551894 PMCID： PMC4993042

Source DB: PubMed Journal: Clin Adv Hematol Oncol ISSN： 1543-0790

58 in total

1. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Authors: J H Turner; P G Claringbold
Journal: Eur J Cancer Date: 1991 Impact factor: 9.162

2. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy.

Authors: N Shimizu; H Masuda; H Yamanaka; N Oriuchi; T Inoue; K Endo
Journal: J Urol Date: 1999-02 Impact factor: 7.450

3. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.

Authors: G M Blake; M A Zivanovic; R M Blaquiere; D R Fine; A J McEwan; D M Ackery
Journal: J Nucl Med Date: 1988-04 Impact factor: 10.057

4. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

Authors: I Resche; J F Chatal; A Pecking; P Ell; G Duchesne; R Rubens; I Fogelman; S Houston; A Fauser; M Fischer; D Wilkins
Journal: Eur J Cancer Date: 1997-09 Impact factor: 9.162

5. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Authors: G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette
Journal: Eur Urol Date: 2003-11 Impact factor: 20.096

6. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

Authors: Marnix G E H Lam; Tjitske B Bosma; Peter P van Rijk; Bernard A Zonnenberg
Journal: Eur J Nucl Med Mol Imaging Date: 2009-03-25 Impact factor: 9.236

7. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Authors: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan Slovin; William K Kelly; Dana Rathkopf; Gretchen A Gignac; David Solit; Lawrence Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph O'Donoghue; Steven Larson; Howard I Scher
Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544

8. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

Authors: A Sella; R Kilbourn; R Amato; C Bui; A A Zukiwski; J Ellerhorst; C J Logothetis
Journal: J Clin Oncol Date: 1994-04 Impact factor: 44.544

9. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.

Authors: Shi-Ming Tu; Paul Mathew; Franklin C Wong; Donnah Jones; Marcella M Johnson; Christopher J Logothetis
Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544

10. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors: Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544

4 in total

1. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Authors: Mehmet Asim Bilen; Marcella M Johnson; Paul Mathew; Lance C Pagliaro; John C Araujo; Ana Aparicio; Paul G Corn; Nizar M Tannir; Franklin C Wong; Michael J Fisch; Christopher J Logothetis; Shi-Ming Tu
Journal: Cancer Date: 2014-08-22 Impact factor: 6.860